Literature DB >> 29880293

The LILAC trial and the blooming of anticancer biosimilars.

Miguel Martin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29880293     DOI： 10.1016/S1470-2045(18)30290-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

Review 1.  Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Authors:  Diana Lüftner; Gary H Lyman; João Gonçalves; Xavier Pivot; Minji Seo
Journal:  Target Oncol       Date:  2020-08       Impact factor: 4.493
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.